Company / Free Cash Flow
Cytokinetics Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$534.8M
FY2025
5-year range
-$534.8M / -$191.4M
FY2021-FY2025
Trend
-33.8%
vs FY2024
Sector context
#187 of 194
Health Care
What the data says
Among 194 Health Care companies, Cytokinetics is in the bottom 4% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$535M in FY2025 to $35M in FY2016.
Based on SEC 10-K filings.
-$535M in FY2025.
Declined from -$416M to -$535M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 194This company -$534.8M Sector average $470.6M
▼
-213.7% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 33.8% year-over-year.
- Ranks #187 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$534.8M | -33.8% |
| FY2024 | -$399.8M | +3.8% |
| FY2023 | -$415.7M | -33.7% |
| FY2022 | -$310.9M | -62.4% |
| FY2021 | -$191.4M | -8975.1% |
| FY2020 | -$2.1M | +97.7% |
| FY2019 | -$93.5M | +8.4% |
| FY2018 | -$102.1M | +2.4% |
| FY2017 | -$104.6M | -395.7% |
| FY2016 | $35.4M | +718.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026